Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Share News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Conexion, Condor, Capcon...

Fri, 18th Jun 2010 13:25

Music copyright group Conexion Media narrowed losses in the year to December 31 despite lower revenues.Pre-tax losses fell to £630,000 from £1.6m on revenues that were down to £3.4m from £4m.Conexion, which specialises in the administration of film and TV related music rights, won deals newspaper publisher Times Group of India and US cable operator Comcast during the period.Shares in Condor Resources were soaring after the metals explorer was granted 45 square kilometres of land which it believes contains a goldfield.Capcon Holdings, the AIM listed investigations and risk management group, swung to a loss of £61,600 in the six months ended 31 March from a 34,100 profit a year ago."Trading in the first half of this financial year, although below the same period last year, has been in line with our expectations," said the firm, which has slashed staff levels and overheads to cope with a slump in demand from the leisure sector.Far East Russia-focused Amur Minerals' application for a mining licence linked to discoveries at the nickel sulphide Kun Maine exploration licence is being reviewed by the Russian authorities.The application, filed in January, can take up to 12 months from submission to approval, it said.Diagnostic screening and testing products designer Akers Biosciences has completed the clinical development of the Breath Ketone "Check" test, which was designed as a potential, significantly improved, replacement for existing blood and urine based testing methods.The company said the product's accuracy was demonstrated during the trials. Akers's point-of-care test has been shown to correlate 100% with blood testing methods, and to do so in minutes via a disposable breath test is a highly encouraging result.Churchill Mining has completed the initial stage of its Indonesian restructuring and has converted its 75% beneficial interest in the Ridlatama Tambang license area into a direct equity interest, taking advantage of a recently introduced Indonesian mining law that allowed foreign companies to take direct equity interests in Indonesian mining companies.Churchill has also converted to a 75% direct ownership in PT Ridlatama Trade Powerindo, which holds a prospective 5,386 hectare license area adjacent to the Ridlatama Tambang license area, on which no drilling has been done to date. Holiday resort developer Minoan Group released interim results that were in line with management expectations. On zero revenues the company sustained a pre-tax loss of £0.56m in the six months to end-March compared to a loss of £0.67m the year before.The company, which is looking to diversify in the tourism and leisure sector, said that any acquisition it makes will be via a special purpose vehicle, almost certainly with external partners with whom parallel discussions are currently in progress.
More News
8 Oct 2018 13:10

Akers Biosciences appoints chief executive after settling legal battle

(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute with Pulse Health.

Read more
15 Aug 2018 08:04

Akers Biosciences profits hit over antigen difficulties

(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid assay products had offset a stronger showing in its breathalyser unit.

Read more
3 Apr 2018 13:45

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.The AIM-listed firm

Read more
16 Mar 2018 18:11

Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

LONDON (Alliance News) - Akers Biosciences Inc, a developer of health screening and testing products, said Friday that it has netted USD48,750 from warrants to

Read more
16 Feb 2017 08:44

Akers Biosciences gains US patent for disposable cartridge

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, has been granted a US patent for its wellness disposable markers. The US Patent and Trademark Office has given a patent for its proprietary cartridge for the optical scanning device used in the company's Brea

Read more
10 Jan 2017 12:06

Akers Biosciences to raise $2m in US placing

(ShareCast News) - Rapid diagnostic test manufacturer Akers Biosciences said it plans to issue $2m of new shares plus warrants over another $1m worth of shares. The AIM- and Nasdaq-listed outfit said funds will be used for working capital as well as to accelerate growth in the US and in internationa

Read more
19 Dec 2016 14:52

Akers Biosciences signs three year deal with US hospital group

(ShareCast News) - Rapid health information technology developer Akers Biosciences announced on Friday it has signed a three-year agreement with the Greater New York Hospital Association to introduce its flagship rapid tests for heparin-induced thrombocytopenia across the association's network of ov

Read more
12 Dec 2016 16:03

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Dec 2016 12:13

Akers Agrees Deal For First Check To Sell Cholesterol Test In US

Read more
10 Nov 2016 09:46

Akers Biosciences gains European patent for ketone breath device

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, gains a European patent for its ketone acid breath device. The European Patent Office has issued a patent covering the company's breath ketone detector, a breath device to monitor ketone levels, which follows

Read more
19 Aug 2016 12:18

Akers Biosciences, ChubeWorkx settle lengthy legal dispute

(ShareCast News) - Akers Biosciences has reached a settlement agreement with former distributor ChubeWorkx Guernsey Ltd, allowing it to recover $1.25m in product and cash and end a lengthy legal dispute between the pair. ChubeWorkx would recover what it was owed from a promissory note by taking deli

Read more
18 Aug 2016 07:22

Akers Says Test Results "Highly Successful" For BreathScan OxiChek

Read more
30 Jun 2016 08:56

Akers Says Rapid Chlamydia Test Trial "Highly Successful"

Read more
27 Jun 2016 08:16

Akers Biosciences Signs First Distribution Deal For BreathScan OxiChek

Read more
26 May 2016 16:27

DIRECTOR DEALINGS: Akers Biosciences Chief Executive Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.